1256393-27-7

Basic information

• Product Name: ledipasvir interMediate
• Synonyms: 2-Azabicyclo[2.2.1]heptane-2-carboxylic acid, 3-[6-[9,9-difluoro-7-[2-[(6S)-5-[(2S)-2-[(Methoxycarbonyl)aMino]-3-Methyl-1-oxobutyl]-5-azaspiro[2.4]hept-6-yl]-1H-iMidazol-5-yl]-9H-fluoren-2-yl]-1H-benziMidazol-2-yl]-, 1,1-diMethylethyl ester, (1R,3S,4S)-;(1R,3S,4S)-3-[6-[9,9-Difluoro-7-[2-[(6S)-5-[(2S)-2-[(methoxycarbonyl)amino]-3-methyl-1-oxobutyl]-5-azaspiro[2.4]hept-6-yl]-1H-imidazol-5-yl]-9H-fluoren-2-yl]-1H-benzimidazol-2-yl]-2-azabicyclo[2.2.1]heptane-2-carboxylic acid 1,1-dimethylethyl ester
• CAS NO: 1256393-27-7
• Molecular Formula: C₄₇H₅₁F₂N₇O₅
• Molecular Weight: 831.9485464
• EINECS: -0
• Mol File: 1256393-27-7.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ledipasvir interMediate(CAS DataBase Reference)
• NIST Chemistry Reference: ledipasvir interMediate(1256393-27-7)
• EPA Substance Registry System: ledipasvir interMediate(1256393-27-7)

Safety Data

• Hazardous Substances Data: 1256393-27-7(Hazardous Substances Data)

Usage

General Description

Ledipasvir intermediate is a chemical compound that is used in the synthesis of ledipasvir, a medication used to treat chronic hepatitis C virus (HCV) infection. The intermediate plays a crucial role in the production of ledipasvir by serving as a building block in the chemical reaction process. It is specifically designed to help create the final molecular structure of ledipasvir, which is an inhibitor of the HCV NS5A protein. The intermediate undergoes various chemical transformations and purification steps to ultimately form ledipasvir, which has been proven to be highly effective in the treatment of HCV infection when used in combination with other antiviral medications. Overall, ledipasvir intermediate is a vital component in the pharmaceutical manufacturing process of ledipasvir, ultimately contributing to the production of a medication that has significantly improved the treatment of chronic HCV infection.

Upstream product

• 1378387-81-5 1-(7-bromo-9,9-difluoro-9-hydrofluoren-2-yl)-2-chloroethanone 
• 1296797-09-5 C₁₄H₂₂N₂O₅ 
• 1256387-87-7 (1R,3S,4S)-3-[6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzimidazol-2-yl]-2-azabicyclo[2.2.1]heptane-2-carboxylic acid 1,1-dimethylethyl ester 
• 111398-44-8 (2R)-2-(methoxycarbonyl amino)-3-methylbutanoic acid 
• 1575-37-7 4-Bromo-benzene-1,2-diamine 
• 1256387-74-2 (1R,3S,4S)-3-(6-bromo-1H-benzimidazol-2-yl)-2-azabicyclo[2.2.1]heptane-2-carboxylic acid 1,1-dimethylethyl ester 
• 1256387-73-1 3-(2-amino-4-bromo-phenylcarbamoyl)-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester 
• 134795-25-8 (1R,3S,4S)-2-aza-bicyclo[2.2.1]heptane-2,3-dicarboxylic acid 2-tert-butyl ester 
• 1256388-50-7 (1-{6-[5-(7-bromo-9,9-difluoro-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-aza-spiro[2.4]heptane-5-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester 
• 1256388-49-4 6-[5-(7-bromo-9,9-difluoro-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-aza-spiro[2.4]heptane-5-carboxylic acid benzyl ester 
• 1256388-48-3 5-aza-spiro[2.4]heptane-5,6-dicarboxylic acid 5-benzyl ester 6-[2-(7-bromo-9,9-difluoro-9H-fluoren-2-yl)-2-oxo-ethyl] ester 
• 14348-75-5 2,7-dibromofluorene-9-one 
• 1229603-71-7 2,7-dibromo-9,9-difluoro-9H-fluorene 
• 111398-44-8 N-methoxycarbonyl-L-valine 

Downstream Products

• 1256388-51-8 methyl [(2S)-1-{(6S)-6-[5-(9,9-difluoro-7-{2-[(1R,3S,4S)-2-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-azabicyclo[2.2.1]-hept-3-yl]-1H-benzimidazol-6-yl}-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-azaspiro[2.4]hept-5-yl}-3-methyl-1-oxobutan-2-yl]carbamate 

Relevant articles and documents

METHOD OF PREPARATION FOR LEDIPASVIR AND DERIVATIVE THEREOF, AND INTERMEDIATE COMPOUND FOR PREPARATION OF LEDIPASVIR

Methods of preparing Ledipasvir and derivatives thereof, and intermediate compounds used in the preparation of Ledipasvir are provided. Specifically, a method for preparing the compounds of formula 1 and a series of preparation methods of preparing Ledipasvir are provided. The methods described herein are simple and efficient, and have better application prospects.

Preparation method of ledipasvir

The invention belongs to the drug synthesis field and particularly relates to a preparation method of ledipasvir. The preparation method comprises the following steps: reacting by virtue of a compound (II) and a compound (III) under the action of alkali, so as to obtain a compound (IV); reacting by virtue of the compound (IV) and a compound (V) under the action of a metal catalyst, so as to obtain a compound (VI); reacting by virtue of the compound (VI) and an amine reagent, so as to obtain a compound (VII); reacting by virtue of the compound (VII) under the action of acid, so as to obtain a compound (VIII); and reacting by virtue of the compound (VIII) and Moc-L-valine under the action of a condensing agent, so as to obtain the ledipasvir represented by a chemical formula (I). The preparation method has the beneficial effects that the process route is short, the operation is simple and convenient, and the reaction yield is high.

METHODS FOR TREATING HCV

This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.